Sign In
Buy AZN
$183.02
+2.00 (+1.10%)
At Close: Jun 24, 2026
Here is What to Know Beyond Why AstraZeneca PLC (AZN) is a Trending Stock
10:33am, Monday, 13'th Nov 2023
Recently, Zacks.com users have been paying close attention to Astrazeneca (AZN). This makes it worthwhile to examine what the stock has in store.
AstraZeneca prioritizes US for RSV drug amid surge in cases
02:22pm, Friday, 10'th Nov 2023
AstraZeneca on Friday said it was prioritizing the U.S. market for additional doses of its respiratory syncytial virus (RSV) drug Beyfortus, which was approved in July to prevent the disease in infant
Who's afraid of Ozempic? From restaurants to package makers, companies work to calm investors' GLP-1 jitters.
11:13am, Friday, 10'th Nov 2023
That's the message from many corporate executives who have lately been peppered with questions about how Wegovy, Ozempic and other drugs widely used for weight loss may impact their bottom line.
AstraZeneca (AZN) Beats on Q3 Earnings & Sales, Ups 2023 View
09:48am, Friday, 10'th Nov 2023
AstraZeneca (AZN) beats third-quarter estimates for earnings and sales. The company raises its sales and EPS guidance for 2023.
AstraZeneca (AZN) Buys Global Rights to Oral Obesity Candidate
09:48am, Friday, 10'th Nov 2023
To cash in on the rising demand for obesity drugs, AstraZeneca (AZN) in-licenses exclusive rights to ECC5004, a novel oral GLP-1RA therapy, from private Chinese biotech Eccogene.
The 7 Next Trillion Dollar Companies to Invest in to Become a Millionaire
09:07am, Friday, 10'th Nov 2023
Millionaires, by investing in equities, are not made overnight. It takes years of grinding in the form of research that a high level of patience should back.
AstraZeneca CEO discusses oral weight loss drug agreement with Eccogene
05:41pm, Thursday, 09'th Nov 2023
AstraZeneca (AZN) is re-entering the weight loss drug market through a new partnership with China's Eccogene. The deal provides AstraZeneca with global rights, excluding China, to develop and commerci
AstraZeneca PLC (AZN) Q3 2023 Earnings Call Transcript
05:22pm, Thursday, 09'th Nov 2023
AstraZeneca PLC (NASDAQ:AZN ) Q3 2023 Earnings Conference Call November 9, 2023 9:00 AM ET Corporate Participants Andy Barnett - Head, Investor Relations Pascal Soriot - Chief Executive Officer Aradha
Jobless Claims Decreased More Than Expected
12:47pm, Thursday, 09'th Nov 2023
Pre-market futures again are coming in slightly higher, working through a two-week period (so far) of generally higher market indices. Although the Dow broke an eight-day winning streak yesterday, it
AstraZeneca Strikes a Deal for an Experimental Weight-Loss Drug and Boosts Its Guidance
12:10pm, Thursday, 09'th Nov 2023
AstraZeneca (AZN) announced a deal for an experimental weight-loss pill and raised its guidance on higher demand for its cancer treatments.
AstraZeneca CFO: Obesity Market Has a Lot of Potential
11:33am, Thursday, 09'th Nov 2023
AstraZeneca CFO Aradhana Sarin discusses the company's third-quarter results and its plans to develop an obesity pill. The treatment developed by closely held Chinese biotech Eccogene is in early-stag
AstraZeneca faces lawsuits in High Court over ‘defective' Covid-19 vaccine
11:08am, Thursday, 09'th Nov 2023
A UK father and a widower have filed lawsuits against AstraZeneca PLC (LSE:AZN), claiming that the Oxford-AstraZeneca Covid-19 vaccine was defective and caused blood clots and brain injuries to their
Astrazeneca (AZN) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
10:57am, Thursday, 09'th Nov 2023
The headline numbers for Astrazeneca (AZN) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street e
AstraZeneca Is Getting Into the Weight-Loss Drug Game. The Stock Needs a Boost.
10:57am, Thursday, 09'th Nov 2023
AstraZeneca has struck a licensing deal worth up to $2 billion for a weight-loss drug. Stockholders are welcoming the move as its shares have lagged behind peers Eli Lilly and Novo Nordisk.
AstraZeneca Paying Up To $2 Billion For Experimental Obesity Pill—As Weight Loss Drug Market Grows
09:56am, Thursday, 09'th Nov 2023
The drug is similar to Ozempic, which is commonly used for diabetes and weight loss.
